GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arno Therapeutics Inc (OTCPK:ARNI) » Definitions » Liabilities-to-Assets

ARNI (Arno Therapeutics) Liabilities-to-Assets : 3.43 (As of Sep. 2016)


View and export this data going back to 2006. Start your Free Trial

What is Arno Therapeutics Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Arno Therapeutics's Total Liabilities for the quarter that ended in Sep. 2016 was $8.07 Mil. Arno Therapeutics's Total Assets for the quarter that ended in Sep. 2016 was $2.36 Mil. Therefore, Arno Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2016 was 3.43.


Arno Therapeutics Liabilities-to-Assets Historical Data

The historical data trend for Arno Therapeutics's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arno Therapeutics Liabilities-to-Assets Chart

Arno Therapeutics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.81 1.95 1.48 1.07 24.89

Arno Therapeutics Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.79 24.89 2.38 5.75 3.43

Competitive Comparison of Arno Therapeutics's Liabilities-to-Assets

For the Biotechnology subindustry, Arno Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arno Therapeutics's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arno Therapeutics's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Arno Therapeutics's Liabilities-to-Assets falls into.



Arno Therapeutics Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Arno Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2015 is calculated as:

Liabilities-to-Assets (A: Dec. 2015 )=Total Liabilities/Total Assets
=8.985/0.361
=24.89

Arno Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2016 is calculated as

Liabilities-to-Assets (Q: Sep. 2016 )=Total Liabilities/Total Assets
=8.07/2.356
=3.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arno Therapeutics  (OTCPK:ARNI) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Arno Therapeutics Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Arno Therapeutics's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Arno Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
200 Route 31 North, Suite 104, Flemington, NJ, USA, 08822
Arno Therapeutics Inc operates as a biopharmaceutical company. It develops drug candidates to treat patients with cancer and other life-threatening diseases. It develops pre-clinical and clinical-stage product under the following name: Onapristone, AR-42, and AR-12. Onapristone is indicated for endometrial, prostate and breast cancer indications, AR-42 is provided for hematological malignancies and solid tumors indications and AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets.
Executives
S Donald Sussman other: See Footnote 1 888 EAST LAS OLAS BLVD, SUITE 710, FORT LAUDERDALE FL 33301
David M Tanen director, officer: Secretary TWO RIVER GROUP HOLDINGS, LLC., 689 FIFTH AVENUE, NEW YORK NY 10022
Tomer Kariv director C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Arie Belldegrun director UCLA SCHOOL OF MEDICINE, 10833 LE CONTE 66-118 CHS BOX 951738, LOS ANGELES CA 9095-1738
Alexander A Zukiwski director, officer: Chief Executive Officer & CMO 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Jay Moorin director C/O PROQUEST INVESTMENTS, L.P, 2430 VANDERBILT BEACH ROAD, #108 - 190, NAPLES FL 34109
Lawrence A Kenyon officer: Chief Financial Officer C/O OUTLOOK THERAPEUTICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Glenn R. Mattes director, officer: President & CEO 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Randy H Thurman director 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Wexford Gp Llc other: No longer own 10% of Issuer C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH CT 33401
Joseph Jacobs other: No longer own 10% of Issuer C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Capital Lp other: No longer own 10% of Issuer 777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Charles E Davidson other: No longer own 10% of Issuer C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Ran Nussbaum 10 percent owner C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Brian Lenz officer: Chief Financial Officer 65 COMMERCE WAY, HACKENSACK NJ 07601

Arno Therapeutics Headlines

No Headlines